Evidence report: The medical treatment of ocular myasthenia (an evidence-based review) - Report of the Quality Standards Subcommittee of the American Academy of Neurology

Neurology

Volumn 68, Issue 24, 2007, Pages 2144-2149

  Benatar, Michael ^a   Kaminski, Henry J ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CORTICOTROPIN; IMMUNOSUPPRESSIVE AGENT; NEOSTIGMINE; PLACEBO; PYRIDOSTIGMINE;

CLINICAL TRIAL; COCHRANE LIBRARY; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; EMBASE; EYE MOVEMENT; HUMAN; MEDLINE; MYASTHENIA; MYASTHENIA GRAVIS; OCULAR MYASTHENIA; PRIORITY JOURNAL; PUBLICATION; REVIEW; RISK; SYMPTOM; TREATMENT OUTCOME;

EID: 34250337206     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000263481.14289.90     Document Type: Review

References (20)

1. Ferrari G, Lovaste M. Epidemiology of myasthenia gravis in the province of Trento (northern Italy). Neuroepidemiology 1992;11:135-142.
2. Phillips LH, Torner JC, Anderson MS, Cox GM. The epidemiology of myasthenia gravis in central and western Virginia. Neurology 1992;42:1888-1893.
3. Robertson N, Deans J, Compston D. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J Neurol Neurosurg Psychiatry 1998;65:492-496.
4. Somnier F, Keiding N, Paulson O. Epidemiology of myasthenia gravis in Denmark. Arch Neurol 1991;48:733-739.
5. Storm-Mathisen A. Epidemiology of myasthenia gravis in Norway. Acta Neurol Scand 1984;70:274-284.
6. Yu Y, Hawkins B, Ip M, Wong V, Woo E. Myasthenia in Hong Kong Chinese: 1. Epidemiology and adult disease. Acta Neurol Scand 1992;86:113-119.
7. Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow-up study. J Neurol Neurosurg Psychiatry 1989;52:1121-1127.
8. Bever CT, Aquino AV, Penn AS, Lovelace RE, Rowland LP. Prognosis of ocular myasthenia. Ann Neurol 1983;14:516-519.
9. Kaminski H, Daroff R. Treatment of ocular myasthenia: steroids only when compelled. Arch Neurol 2000;57:752-753.
10. Agius M. Treatment of ocular myasthenia with corticosteroids: yes. Arch Neurol 2000;57:750-751.
11. Hachinski V. Treatment of ocular myasthenia. Arch Neurol 2000;57:753.
12. Gronseth G, Baroh R. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review). Neurology 2000;55:636-643.
13. Jaretzki A, Barohn R, Ernstoff R, Kaminski H, Keesey J, Penn A, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16-23.
14. Mount F. Corticotropin in treatment of ocular myasthenia: a controlled clinical trial. Arch Neurol 1964;11:114-124.
15. Badrising U, Brandenburg H, van Hilten J, Brietl P, Wintzen A. Intranasal neostigmine as add-on therapy in myasthenia gravis. J Neurol 1996;243:S59.
16. Papapetropoulos TH, Ellul J, Tsibri E. Development of generalized myasthenia gravis in patients with ocular myasthenia gravis. Arch Neurol 2003;60:1491-1492.
17. Mee J, Paine M, Byrne E, King J, Reardon K, O'Day J. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol 2003;23:251-255.
18. Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 2003;60:243-248.
19. Monsul NT, Patwa HS, Knorr AM, Lesser RL, Goldstein JM. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci 2004;217:131-133.
20. Sommer N, Sigg B, Melms A, Weller M, Schepelmann K, Herzau V, et al. Ocular myasthenia gravis: response to long-term immunosuppressant treatment. J Neurol Neurosurg Psychiatry 1997;62:156-162.